ESSURE ESS305

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a consumer,foreign,other report with the FDA on 2020-03-27 for ESSURE ESS305 manufactured by Bayer Pharma Ag.

Event Text Entries

[188720402] This case was initially received via regulatory authority ((b)(6), reference number: (b)(4)) on 24-mar-2020. This spontaneous case was reported by a consumer and describes the occurrence of pelvic pain ('pelvic pain') in a (b)(6) year old female patient who had essure (batch no. 948837) inserted. The occurrence of additional non-serious events is detailed below. Medical conditions: tests for allergy to nickel, tin, heavy metals were performed. On (b)(6) 2012, the patient had essure inserted. On (b)(6) 2012, the patient experienced pelvic pain (seriousness criteria medically significant and intervention required), fatigue ("chronic fatigue"), menstruation irregular ("periods/bleeding with irregular cycles"), ovarian cyst ("inflammatory flare-ups of follicles during periods"), vaginal cyst ("vaginal cysts"), vaginal discharge ("odorous vaginal discharge"), musculoskeletal pain ("muscle and joint pain"), arthritis ("arthritis"), tendonitis ("tendinitis"), limb discomfort ("heavy legs with fluid retention"), oedema peripheral ("heavy legs with fluid retention"), gait disturbance ("difficulty walking"), migraine ("migraine"), alopecia ("hair loss"), loss of libido ("loss of libido"), memory impairment ("memory loss/forgetting words"), cough ("dry cough"), hot flush ("hot flushes"), adenomyosis ("adenomyosis") and asthenia ("asthenia") and was found to have weight increased ("weight gain"). The patient was treated with surgery (ovary-sparing total hysterectomy with bilateral salpingectomy). Essure was removed on (b)(6) 2020. At the time of the report, the pelvic pain, fatigue, menstruation irregular, ovarian cyst, vaginal cyst, vaginal discharge, musculoskeletal pain, arthritis, tendonitis, limb discomfort, oedema peripheral, gait disturbance, weight increased, migraine, alopecia, loss of libido, memory impairment, cough, hot flush and adenomyosis was resolving and the asthenia had not resolved. The reporter provided no causality assessment for adenomyosis, alopecia, arthritis, asthenia, cough, fatigue, gait disturbance, hot flush, limb discomfort, loss of libido, memory impairment, menstruation irregular, migraine, musculoskeletal pain, oedema peripheral, ovarian cyst, pelvic pain, tendonitis, vaginal cyst, vaginal discharge and weight increased with essure. The reporter commented: the reporter informed that the patient had adenomyosis despite a novasure procedure performed on (b)(6) 2013 (endometrial removal). Since device removal the consequences were asthenia and physical and mental sequelae following the many symptoms that she suffered for just over 7 years. It was also reported an improvement in the symptoms since removal of essure, however a persistence of asthenia. A technical investigation will be conducted, including a batch review, and a review of complaint records and other relevant data; should any new and reportable information become available from our investigation, this will be provided in a supplementary report.
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report Number2951250-2020-02770
MDR Report Key9888629
Report SourceCONSUMER,FOREIGN,OTHER
Date Received2020-03-27
Date of Report2020-04-01
Date of Event2012-11-28
Date Mfgr Received2020-03-24
Device Manufacturer Date2012-02-01
Date Added to Maude2020-03-27
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactK SHAW LAMBERSON
Manufacturer Street100 BAYER BLVD, P.O. BOX 915
Manufacturer CityWHIPPANY NJ 07981
Manufacturer CountryUS
Manufacturer Postal07981
Manufacturer G1BAYER PHARMA AG
Manufacturer StreetM
Manufacturer CityBERLIN, 13353
Manufacturer CountryGM
Manufacturer Postal Code13353
Single Use3
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NameESSURE
Generic NameTRANSCERVICAL CONTRACEPTIVE TUBAL OCCLUSION DEVICE
Product CodeHHS
Date Received2020-03-27
Model NumberESS305
Lot Number948837
Device Expiration Date2015-02-01
OperatorHEALTH PROFESSIONAL
Device AvailabilityN
Device AgeDA
Device Eval'ed by MfgrN
Device Sequence No1
Device Event Key0
ManufacturerBAYER PHARMA AG
Manufacturer AddressM?LLERSTR. 178 BERLIN, 13353 GM 13353


Patients

Patient NumberTreatmentOutcomeDate
101. Other; 2. Required No Informationntervention 2020-03-27

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.